We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kraig Biocraft Laboratories Inc (QB) | USOTC:KBLB | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.003 | 3.33% | 0.093 | 0.0867 | 0.094 | 0.0943 | 0.089 | 0.09 | 409,896 | 21:15:35 |
Wyoming
|
|
83-0459707
|
(State
or Other Jurisdiction of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2723
South State St. Suite 150
Ann
Arbor, Michigan 48104
|
|
(734)
619-8066
|
(Address
of Principal Executive Offices)
|
|
(Registrant
’
s
Telephone Number)
|
Large
accelerated filer
☐
|
Accelerated
filer
☐
|
Non-accelerated
filer
☑
|
Smaller
reporting company
☑
Emerging
growth company
☐
|
|
|
Page
|
PART I
|
|
|
|
|
|
ITEM
1.
|
DESCRIPTION OF
BUSINESS
|
4
|
ITEM
1A.
|
RISK
FACTORS
|
8
|
ITEM
1B.
|
UNRESOLVED STAFF
COMMENTS
|
8
|
ITEM
2.
|
DESCRIPTION OF
PROPERTY
|
8
|
ITEM
3.
|
LEGAL
PROCEEDINGS
|
8
|
ITEM
4.
|
MINE SAFETY
DISCLOSURES
|
8
|
|
|
|
PART II
|
|
|
|
|
|
ITEM
5.
|
MARKET FOR
REGISTRANT
’
S COMMON
EQUITY; RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES
|
8
|
ITEM
6.
|
SELECTED FINANCIAL
DATA
|
9
|
ITEM
7.
|
MANAGEMENT
’
S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
9
|
ITEM
7A.
|
QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
13
|
ITEM
8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
13
|
ITEM
9.
|
CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
|
34
|
ITEM
9A.
|
CONTROLS AND
PROCEDURES
|
34
|
ITEM
9B.
|
OTHER
INFORMATION
|
35
|
|
|
|
PART III
|
|
|
|
|
|
ITEM
10.
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
35
|
ITEM
11.
|
EXECUTIVE
COMPENSATION
|
37
|
ITEM
12.
|
SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS
|
39
|
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
39
|
ITEM
14.
|
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
|
40
|
|
|
|
PART IV
|
|
|
|
|
|
ITEM
15.
|
EXHIBITS
|
41
|
|
|
|
SIGNATURES
|
|
43
|
|
Material Toughness (1)
|
Tensile Strength (2)
|
Weight (3)
|
Dragline spider
silk
|
120,000-160,000
|
1,100-2,900
|
1.18-1.36
|
|
|
|
|
Steel
|
2,000-6,000
|
300-2,000
|
7.84
|
1
|
Measured by the energy required to
break a continuous filament, expressed in joules per kilogram
(J/kg). A .357 caliber bullet has approximately 925 joules of
kinetic energy at impact.
|
2
|
Tensile strength refers to the
greatest longitudinal stress the fiber can bear, measured by force
over area in units of newtons per square meter. The measurement
here is in millions of pascals.
|
3
|
In grams per cubic centimeter of
material.
|
●
|
Medical
textiles;
|
●
|
Geotextiles;
|
●
|
Textiles
used in Defense and Military;
|
●
|
Safe
and Protective Clothing;
|
●
|
Filtration
Textiles;
|
●
|
Textiles
used in Transportation;
|
●
|
Textiles
used in Buildings;
|
●
|
Composites
with Textile Structure;
|
●
|
Functional
and Sportive Textiles.
|
Marks
|
Registered Owner
|
Country
|
Status
|
Monster
SilkTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
SpiderpillarTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
SpilkTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Monster
WormTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Spider
WormTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Spider
MothTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
●
|
We plan
to accelerate both our microbiology and selective breeding programs
as well as providing more resources for our material testing
protocols into 2019. We spent approximately $148,069 over the last
12 months on research and development of high strength polymers. In
2018 we directed our research and development efforts on growing
our internal capabilities. We will consider renewing funding of the
collaborative research and development of high strength polymers at
the University of Notre Dame in 2019.
|
|
|
|
|
●
|
We
expect to spend approximately $13,700 on collaborative research and
development of high strength polymers and spider silk protein at
the University of Wyoming over the next twelve months. This level
of research spending at the university is also a requirement of our
licensing agreement with the university.
|
|
|
|
|
●
|
We plan
to complete renovations of our Quang Nam, Vietnam factory and begin
commercial scale production of our recombinant spider silk in
Vietnam according to our investment and enterprise registration
certificates.
|
|
|
●
|
We
will consider buying an established revenue producing company in a
compatible business, in order to broaden our financial base and
facilitate the commercialization of our products. We expect to use
a combination of stock and cash for any such purchase.
|
|
|
|
|
●
|
We will
also actively consider pursuing collaborative research
opportunities with both private and university laboratories in
areas of research which overlap the company’s existing
research and development. One such potential area for collaborative
research which the company is considering is protein expression
platforms. If our financing allows, management will give strong
consideration to increasing the breadth of our research to include
protein expression platform technologies.
|
|
|
|
|
●
|
We plan
to actively pursue collaborative research and product testing,
opportunities with companies in the biotechnology, materials,
textile and other industries.
|
|
|
|
|
●
|
We plan
to actively pursue collaborative commercialization, marketing and
manufacturing opportunities with companies in the textile and
material sectors for the fibers we developed and for any new
polymers that we create in 2019.
|
|
|
|
|
●
|
We plan
to actively pursue the development of commercial scale production
of our recombinant materials including Monster Silk
®
and Dragon
SilkTM.
|
|
Year Ended
|
|
%
Change
|
|
|
December 31
|
Increase
(Decrease)
|
|
|
|
2018
|
2017
|
Change
|
|
NET
REVENUES
|
$
401,620
|
$
97,318
|
304,302
|
312.69
%
|
OPERATING
EXPENSES:
|
|
|
|
|
General
and Administrative
|
515,875
|
1,217,050
|
(701,175
)
|
-57.61
%
|
Professional
Fees
|
157,976
|
322,215
|
(164,239
)
|
-50.97
%
|
Officer's
Salary
|
528,127
|
444,596
|
83,531
|
18.79
%
|
Rent
- Related Party
|
11,520
|
10,560
|
960
|
9.09
%
|
Research
and Development
|
148,069
|
258,892
|
(110,823
)
|
-42.81
%
|
Total operating expenses
|
1,361,567
|
2,253,313
|
(891,746
)
|
-39.57
%
|
Loss from operations
|
(959,947
)
|
(2,155,995
)
|
1,196,048
|
-55.48
%
|
Gain
on forgiveness of debt
|
19,924
|
-
|
19,924
|
100.00
%
|
Interest
expense
|
(228,954
)
|
(177,105
)
|
(51,849
)
|
29.28
%
|
Net Loss
|
$
(1,168,977
)
|
$
(2,333,100
)
|
1,164,123
|
-49.90
%
|
|
December 31, 2018
|
December 31, 2017
|
Cash
|
$
13,697
|
$
18,150
|
Accounts
receivable
|
$
-
|
$
25,872
|
Prepaid
expenses
|
$
6,858
|
$
4,465
|
Total
current assets
|
$
20,555
|
$
48,487
|
Total
assets
|
$
71,383
|
$
114,499
|
Total
current liabilities
|
$
4,530,606
|
$
3,490,305
|
Total
liabilities
|
$
4,530,606
|
$
3,490,305
|
PAGE
|
14
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
|
|
|
PAGE
|
15
|
BALANCE
SHEETS AS OF DECEMBER 31, 2018 AND DECEMBER 31, 2017.
|
|
|
|
PAGE
|
16
|
STATEMENTS
OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2018 AND DECEMBER
31, 2017.
|
|
|
|
PAGE
|
17
|
STATEMENTS
OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2018 AND DECEMBER
31, 2017.
|
|
|
|
PAGES
|
18
|
STATEMENT
OF CHANGES IN STOCKHOLDERS
’
DEFICIT FOR THE PERIOD FROM
DECEMBER 31, 2016 TO DECEMBER 31, 2018.
|
|
|
|
PAGES
|
19
|
NOTES
TO FINANCIAL STATEMENTS.
|
Kraig
Biocraft Laboratories, Inc. and Subsidiary
|
||
Consolidated
Statements of Cash Flows
|
||
|
For
the Years Ended December 31,
|
|
|
|
|
|
2018
|
2017
|
Cash
Flows From Operating Activities:
|
|
|
Net
Loss
|
$
(1,168,977
)
|
$
(2,333,100
)
|
Adjustments
to reconcile net loss to net cash used in operations
|
|
|
Depreciation
expense
|
26,632
|
20,291
|
Gain
on forgiveness of debt
|
(19,924
)
|
-
|
Imputed
interest - related party
|
11,909
|
2,623
|
Warrants
issued to consultants
|
72,575
|
848,011
|
Warrants
issued to related party
|
-
|
17,473
|
Changes
in operating assets and liabilities:
|
|
|
(Increase)
Decrease in prepaid expenses
|
(2,394)
|
(6,658
)
|
(Increase)
Decrease in accounts receivables, net
|
25,872
|
5,986
|
Increase
in accrued expenses and other payables - related party
|
682,976
|
551,237
|
Increase
in accounts payable
|
136,326
|
164,595
|
Net
Cash Used In Operating Activities
|
(235,005
)
|
(729,542
)
|
|
|
|
Cash
Flows From Investing Activities:
|
|
|
Purchase of Fixed
Assets and Domain Name
|
(11,448
)
|
(31,167
)
|
Net
Cash Used In Investing Activities
|
(11,448
)
|
(31,167
)
|
|
|
|
Cash
Flows From Financing Activities:
|
|
|
Proceeds from Notes
Payable - related party
|
242,000
|
30,000
|
Proceeds from
issuance of common stock
|
-
|
450,000
|
Net
Cash Provided by Financing Activities
|
242,000
|
480,000
|
|
|
|
Net
Increase in Cash
|
(4,453
)
|
(280,709
)
|
|
|
|
Cash at Beginning
of Period
|
18,150
|
298,859
|
|
|
|
Cash
at End of Period
|
$
13,697
|
$
18,150
|
|
|
|
Supplemental
disclosure of cash flow information:
|
|
|
|
|
|
Cash paid for
interest
|
$
10
|
$
-
|
Cash paid for
taxes
|
$
-
|
$
-
|
|
|
|
Supplemental
disclosure of non-cash investing and financing
activities:
|
|
|
Shares
issued in connection with cashless warrants exercise
|
$
-
|
$
1,703,115
|
Shares
issued from stock payable
|
$
-
|
$
-
|
Settlement of accounts payable with stock issuance
|
$
1,076
|
$
32,850
|
|
December
31, 2018
|
September
30, 2017
|
Stock Warrants
(Exercise price - $0.001/share)
|
36,400,000
|
47,800,000
|
Convertible
Preferred Stock
|
2
|
2
|
Total
|
36,400,002
|
47,800,002
|
|
2018
|
2017
|
|
|
|
Expected income tax
recovery (expense) at the statutory rate of 34% in 2017; 21% in
2018
|
$
(1,412,328
)
|
$
(793,170
)
|
Tax effect of
expenses that are not deductible for income tax purposes (net of
other amounts deductible for tax purposes)
|
11,057
|
294,265
|
Change in valuation
allowance
|
(1,423,384)
|
498,906
|
|
|
|
Provision for
income taxes
|
$
-
|
$
-
|
|
|
|
|
°
|
Level 1
- Valuations based on quoted prices in active markets for identical
assets or liabilities that an entity has the ability to
access. We believe our carrying value of level 1
instruments approximate their fair value at December 31, 2018 and
December 31, 2017.
|
°
|
Level 2
- Valuations based on quoted prices for similar assets or
liabilities, quoted prices for identical assets or liabilities in
markets that are not active, or other inputs that are observable or
can be corroborated by observable data for substantially the full
term of the assets or liabilities.
|
°
|
Level 3
- Valuations based on inputs that are supported by little or no
market activity and that are significant to the fair value of the
assets or liabilities. We consider depleting assets, asset
retirement obligations and net profit interest liability to be
Level 3. We determine the fair value of Level 3
assets and liabilities utilizing various inputs, including NYMEX
price quotations and contract terms.
|
|
December
31, 2018
|
December
31, 2017
|
Level
1
|
$
-
|
$
-
|
Level
2
|
$
-
|
$
-
|
Level
3
|
$
-
|
$
-
|
Total
|
$
-
|
$
-
|
Customer
|
December
31, 2018
|
December
31, 2017
|
Customer
A
|
-
|
100
%
|
Customer
A
|
$
-
|
$
25,872
|
Customer
|
December
31, 2018
|
September
30, 2017
|
Customer
A
|
100
%
|
0
%
|
Customer
A
|
$
401,620
|
$
--
|
|
As
of December 31, 2018
|
December
31, 2017
|
Automobile
|
$
41,805
|
$
41,805
|
Laboratory Equipment
|
73,194
|
61,746
|
Office Equipment
|
7,260
|
7,260
|
Leasehold
Improvements
|
7,938
|
7,938
|
Less: Accumulated
Depreciation
|
(82,887
)
|
(56,255
)
|
Total Property and Equipment,
net
|
$
47,310
|
$
62,494
|
Expected
dividends
|
0
%
|
Expected
volatility
|
78.58
%
|
Expected
term
|
3
years
|
Risk free
interest rate
|
1.32
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
93.6
%
|
Expected
term
|
4
years
|
Risk free
interest rate
|
1.01
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
93.60
%
|
Expected
term
|
4
years
|
Risk free
interest rate
|
1.01
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
107.51
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
0.82
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
106.40
%
|
Expected
term
|
3
years
|
Risk free
interest rate
|
1.43
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
106.57
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
1.15
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
102.65
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
1.38
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
96.95
%
|
Expected
term
|
3
years
|
Risk free
interest rate
|
2.26
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
97.56
%
|
Expected
term
|
4
years
|
Risk free
interest rate
|
2.65
%
|
Expected
forfeitures
|
0
%
|
|
Number
of
Warrants
|
Weighted
Average Exercise Price
|
Weighted
Average Remaining Contractual Life (in Years)
|
Balance, December
31, 2017
|
32,800,000
|
|
3.0
|
Granted
|
3,600,000
|
-
|
|
Exercised
|
-
|
-
|
|
Cancelled/Forfeited
|
-
|
-
|
|
Balance, December
31, 2018
|
36,400,000
|
|
2.9
|
Intrinsic
Value
|
$
1,783,600
|
|
|
Exercise
Price Warrants Outstanding
|
Warrants Exercisable
|
Aggregate Intrinsic
Value
|
|
|
|
|
|
$
0.001
|
31,100,000
|
2.9
|
$
1,523,900
|
$
0.056
|
3,000,000
|
2.6
|
$
147,000
|
$
0.04
|
2,300,000
|
2.7
|
$
112,700
|
Exercise Price Warrants Outstanding
|
Warrants Exercisable
|
Weighted Average Remaining Contractual
Life
|
Aggregate Intrinsic Value
|
|
|
|
|
$0.001
|
30,500,000
|
2.5
|
$2,639,000
|
$0.04
|
2,300,000
|
3.1
|
$133,400
|
●
|
Common
stock Class A, unlimited number of shares authorized, no par
value
|
●
|
Common
stock Class B, unlimited number of shares authorized, no par
value
|
●
|
Preferred
stock, unlimited number of shares authorized, no par
value
|
●
|
Calm
Seas has purchased an aggregate of $7,500,000 of our Class A common
stock; or
|
●
|
The
second anniversary from the Effective Date.
|
–
|
Lack of internal audit function
.
During 2018, the Company, upon review
of the independent auditors, made some adjustments to its financial
statements, including, adjusting salary amounts and the related tax
accruals, correcting warrant expense for a warrant issued to a
related party, and adding the liability due to our attorney that
should have been recorded.
Management believes that the
foregoing is due to the fact that the Company lacks qualified
resources to perform the internal audit functions properly and that
the scope and effectiveness of the internal audit function are yet
to be developed. Specifically, the reporting mechanism between the
accounting department and the Board of Directors and the CEO was
not effective, therefore resulting in the delay of recording and
reporting.
|
|
|
–
|
No Segregation of Duties Ineffective controls over financial
reporting
: As of December 31, 2018, we had no full-time
employees with the requisite expertise in the key functional areas
of finance and accounting. As a result, there is a lack of proper
segregation of duties necessary to insure that all transactions are
accounted for accurately and in a timely manner.
|
|
|
–
|
Lack of a functioning audit committee
: Due to a lack of a
majority of independent members and a lack of a majority of outside
directors on our board of directors, and no audit committee has
been elected, the oversight in the establishment and monitoring of
required internal controls and procedures is
inadequate.
|
|
|
–
|
Written Policies & Procedures
: Due to lack of written
policies and procedures for accounting and financial reporting, the
Company did not establish a formal process to close our books
monthly and account for all transactions.
|
|
|
–
|
Lack
of controls over related party transactions:
As of
December 31, 2018, the Company did not establish a formal written
policy for the approval, identification and authorization of
related party transactions.
|
1.
|
We will
continue to educate our management personnel to increase its
ability to comply with the disclosure requirements and financial
reporting controls; and
|
2.
|
We will
increase management oversight of accounting and reporting functions
in the future; and
|
3.
|
As soon
as we can raise sufficient capital or our operations generate
sufficient cash flow, we will hire personnel to handle our
accounting and reporting functions.
|
NAME
|
AGE
|
POSITION
|
DATE APPOINTED
|
Kim
Thompson
|
57
|
President, Chief
Executive Officer, Chief Financial Officer and
Director
|
April 25,
2006
|
Jonathan R.
Rice
|
39
|
Chief Operating
Officer
|
January 20,
2015
|
Name and principal position
|
Year
|
Salary ($)
|
Bonus ($)
|
Stock Awards ($)
|
Option Awards ($)
|
Non-Equity Incentive Plan Compensation ($)
|
Nonqualified Deferred Compensation Earnings ($)
|
All Other Compensation ($)
|
Total ($)
|
Kim Thompson
President, CEO, CFO and Director
|
2018
|
$
334,708
|
$
66,942
|
$
0
|
$
0
|
$
0
|
$
0
|
$
55,934
(1)
|
$
457,584
|
|
2017
|
$
315,764
|
$
0
|
$
0
|
$
0
|
$
0
|
$
0
|
$
47,140
(2)
|
$
362,902
|
Jonathan R. Rice
COO
|
2018
|
$
126,477
|
$
20,000
(3)
|
$
0
|
$
0
|
$
0
|
$
0
|
$
15,808
(4)
|
$
162,285
|
|
2017
|
$
124,834
|
$
4,000
|
$
0
|
$
17,473
|
$
0
|
$
0
|
$
16,970
(5)
|
$
163,277
|
(1)
|
In
2018, Kim Thompson received $48,565 in medical insurance and
medical reimbursement pursuant to an employment agreement entered
into with us. In 2018, Kim Thompson received $7,161 in
reimbursement for office and travel related expenses.
|
(2)
|
In
2017, Kim Thompson received $31,997 in medical insurance and
medical reimbursement pursuant to an employment agreement entered
into with us. In 2017, Kim Thompson received $15,143 in
reimbursement for office and travel related expenses.
|
(3)
|
In 2018, Jonathan Rice was owed a $20,000 bonus payable in March
2018, that bonus has not been paid.
|
(4)
|
In
2018, Jonathan Rice received $14,285 in medical insurance and
medical reimbursement, $1,523 in phone service expenses and travel
related, pursuant to an employment agreement entered into with
us
.
Mr
Rice was owed a $20,000 bonus payable in March 2018, that bonus has
not been paid.
|
(5)
|
In
2017, Jonathan Rice received $15,930 in medical insurance and
medical reimbursement, $1,040 in phone service expenses, pursuant
to an employment agreement entered into with us
.
|
|
2018
|
2017
|
Audit
Fees
|
$
15,450
|
$
17,900
|
Audit-Related
Fees
|
$
-
|
-
|
Tax
Fees
|
$
13,385
|
$
27,352
|
All Other
Fees
|
$
-
|
-
|
Total
|
$
28,835
|
$
45,252
|
●
|
approved
by our audit committee; or
|
●
|
entered
into pursuant to pre-approval policies and procedures established
by the audit committee, provided the policies and procedures are
detailed as to the particular service, the audit committee is
informed of each service, and such policies and procedures do not
include delegation of the audit committee's responsibilities to
management.
|
1.
|
The financial statements listed in the
“
Index to Financial
Statements
”
at page F-1
are filed as part of this report. The financial statements listed
in the
“
Index to
Financial Statements
”
at
page F-1 are filed as part of this report.
|
2.
|
Financial statement schedules are omitted
because they are not applicable or the required information is
shown in the financial statements or notes thereto.
|
3.
|
Exhibits included or incorporated herein: see
index to Exhibits.
|
(b) Exhibits
|
|
|
EXHIBIT NUMBER
|
|
DESCRIPTION
|
|
|
|
3.1
|
|
Articles
of Incorporation
(1)
|
|
|
|
3.2
|
|
Articles
of Amendment
(3)
|
|
|
|
3.3
|
|
Articles
of Amendment, filed with the Wyoming Secretary of State on November
15, 2013
(6)
|
|
|
|
3.4
|
|
Articles
of Amendment, filed with the Wyoming Secretary of State on December
17, 2013
(7)
|
|
|
|
3.5
|
|
By-Laws
(1)
|
|
|
|
4.1
|
|
Form of
Warrant issued Mr. Jonathan R. Rice
|
|
|
|
10.1
|
|
Employment
Agreement, dated November 10, 2010, by and between Kraig Biocraft
Laboratories, Inc. and Kim Thompson
(8)
|
|
|
|
10.2
|
|
Securities
Purchase Agreement between Kraig Biocraft Laboratories and Worth
Equity Fund, L.P. and Mutual Release
(1)
|
10.3
|
|
Securities
Purchase Agreement between Kraig Biocraft Laboratories and Lion
Equity
(1)
|
|
|
|
10.4
|
|
Amended
Letter Agreement, dated September 14, 2009, by and between Kraig
Biocraft Laboratories and Calm Seas Capital, LLC
(3)
|
|
|
|
10.5
|
|
Exclusive
License Agreement, effective as of May 8, 2006, by and between The
University of Wyoming and Kraig Biocraft Laboratories,
Inc.
(2)
|
|
|
|
10.6
|
|
Addendum
to the Founder
’
s Stock
Purchase and Intellectual Property Transfer Agreement, dated
December 26, 2006, and the Founder
’
s Stock Purchase and Intellectual
Property Transfer Agreement dated April 26, 2006
(3)
|
|
|
|
10.7
|
|
Intellectual
Property/Collaborative Research Agreement, dated March 20, 2010, by
and between Kraig Biocraft Laboratories and The University of Notre
Dame du Lac.
(2)
|
|
|
|
10.8
|
|
Letter
Agreement, dated June 28, 2011, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC
(4)
|
|
|
|
10.9
|
|
Letter
Agreement, dated April 30, 2013, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC
(5)
|
|
|
|
10.1
|
|
Letter
Agreement, dated October 2, 2014, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC
(10)
|
|
|
|
10.11
|
|
License
Agreement, dated October 28, 2011, between the Company and
University of Notre Dame du Lac.
(12)
|
|
|
|
10.12
|
|
Intellectual
Property / Collaborative Research Agreement, dated June 6, 2012,
between the Company and University of Notre Dame du
Lac.
(12)
|
|
|
|
10.13
|
|
Collaborative
Yarn and Textile Development Agreement, dated September 30, 2013,
between the Company and Warwick Mills, Inc.
(12)
|
|
|
|
10.14
|
|
Employment
Agreement, dated January 19, 2015, between the Company and Mr.
Jonathan R. Rice
(11)
|
|
|
|
10.15
|
|
Intellectual
Property and Collaborative Research Agreements, dated March 4,
2015, between the Company and University of Notre Dame du
Lac.
|
|
|
|
14.1
|
|
Code of
Business Conduct and Ethics
(13)
|
|
|
|
21.1
|
|
Subsidiaries*
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer/Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002 *
|
|
|
|
31.2
|
|
Certification
of Chief Executive Officer/Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 *
|
|
|
|
101
|
|
Interactive
data files #
|
|
Kraig Biocraft Laboratories, Inc.
|
|
|
|
|
|
|
Dated:
March 29, 2019
|
By:
|
/s/ Kim Thompson
|
|
|
|
Kim
Thompson
|
|
|
|
President,
Chief Executive Officer and Chief Financial Officer
|
|
|
|
(Principal
Executive Officer and Principal Financial and Accounting
Officer)
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Kim Thompson
|
|
President,
Chief Executive Officer, Chief Financial Officer and Sole
Director
|
|
March
29, 2019
|
Kim Thompson
|
|
|
|
|
1 Year Kraig Biocraft Laborator... (QB) Chart |
1 Month Kraig Biocraft Laborator... (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions